[Federal Register Volume 60, Number 191 (Tuesday, October 3, 1995)] [Rules and Regulations] [Pages 51718-51719] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 95-24593] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 522 Implantation or Injectable Dosage Form New Animal Drugs; Ceftiofur Sterile Powder For Injection AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by The Upjohn Co. The supplemental NADA provides for veterinary prescription use of a reconstituted ceftiofur sterile powder for injection for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) in cattle. EFFECTIVE DATE: October 3, 1995. FOR FURTHER INFORMATION CONTACT: Naba K. Das, Center for Veterinary Medicine (HFV-133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1659. SUPPLEMENTARY INFORMATION: The Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001, filed a supplemental NADA 140-338, which provides for veterinary prescription use of Naxcel(ceftiofur sodium) sterile powder for intramuscular use in cattle for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus. The reconstituted drug contains the equivalent of 50 milligrams (mg) of ceftiofur per milliliter used at 0.5 to 1.0 mg/pound of body weight once daily for up to 5 days. The supplemental NADA is approved as of August 24, 1995, and the regulations are amended in 21 CFR 522.313(d) to reflect the approval. The basis of approval is discussed in the freedom of information summary. [[Page 51719]] In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. to 4 p.m., Monday through Friday. Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval qualifies for a 3-year marketing exclusivity beginning August 24, 1995, because the application contains reports of new clinical or field investigations (other than bioequivalence or residue studies) and, in the case of food producing animals, human food safety studies (other than bioequivalence or residue studies) essential to the approval and conducted or sponsored by the applicant. The exclusivity applies only to the new indication which is the subject of this supplement. The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. List of Subjects in 21 CFR Part 522 Animal drugs. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows: PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS 1. The authority citation for 21 CFR part 522 continues to read as follows: Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). 2. Section 522.313 is amended by adding a sentence to the end of paragraph (d)(1)(ii) to read as follows: Sec. 522.313 Ceftiofur sterile powder for injection. * * * * * (d) * * * (1) * * * (ii) * * * Also, for the treatment of acute bovine interdigitial necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus. * * * * * Dated: September 25, 1995. Stephen F. Sundlof, Director, Center for Veterinary Medicine. [FR Doc. 95-24593 Filed 10-2-95; 8:45 am] BILLING CODE 4160-01-F